Aquestive Therapeutics, Inc. (AQST) research

Aquestive Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$4.95
As of

Aquestive Therapeutics, Inc. (AQST): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-17.

As of . Source: SEC EDGAR filings for AQST. Method and limitations.

SHARE THIS CARD

Share the AQST intelligence card

A branded snapshot of AQST: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion AQST intelligence card preview
Post to X
LIVE TERMINAL

See AQST live in the terminal

Track AQST's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live AQST terminal, free

Active signals for AQST

FREE, NO ACCOUNT

Every signal on AQST, as it fires

You are seeing 5 of 18 signals recorded on AQST since 2026-06-10.

The five above all landed on 2026-09-06. The other 13 were recorded on 3 other days. 14 of the 18 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in AQST (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 03843E104 · 2026Q2$5.3M0.00%,
CITADEL ADVISORS LLCCUSIP 03843E104 · 2026Q2$1.9M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 03843E104 · 2026Q2$1.7M0.00%,
D. E. Shaw & Co., Inc.CUSIP 03843E104 · 2026Q2$157K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, AQST

AQST against its peers

AQST's operating margin of -159.5% ranks in the 3rd percentile of 18 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.

MetricAQSTPeer medianPercentilen
Revenue FY44.5M USD269M USD817
Gross marginn/a48.9%n/a15
Operating margin-159.5%-2.7%318
Net margin-188.1%-15.3%318
Return on equityn/a-22.2%n/a17

Peers (20): VREOF, TLRY, EOLS, KMDA, TKNO, NIKA, VRNO, CGC, CRLBF, ELTP, CRON, HROW, AKBA, CRDL, TSNDF, GTBIF, ETON, DERM, PRGO, ALVO. Left out: EVO (period gap), BORAY (no annual filing), PHBI (period gap), LFCR (no annual filing), OGI (period gap). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AQST: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more AQST signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AQSTand get the insider, 13F, options, and confluence read in one view.

Open the live AQST terminal, free